<?xml version="1.0" encoding="UTF-8"?>
<p class="p">This study was conducted at Citoxlab North America (Laval, Quebec, Canada) according to their standard operating procedures but not under good laboratory practice regulations. The study was designed with the reference to the following guidelines: CVM guidance for industry #56: protocol development guideline for clinical effectiveness and target animal safety trials; CVM guidance for industry #221: recommendations for preparation and submission of animal food additive petitions; VICH GL43 (CVM GFI #185): guidance for industry: target animal safety for veterinary pharmaceutical products; AAFCO dog food gestation/lactation and growth feeding protocols. The CVM is the Center of Veterinary Medicine, a division of the US Food and Drug Administration (FDA). Procedures involving the care and use of animals in the study were approved by the Institutional Animal Care and Use Committee prior to conduct. During the study, the care and use of animals were conducted in accordance with the principles outlined in the current guidelines published by the Canadian Council on Animal Care and the guide for the care and use of laboratory animals, an NRC publication and USDA regulations. Citoxlab North America facility is accredited by the Canadian Council on Animal Care and AAALAC.</p>
